

Summary of 3rd Quarter Financial Results for year ended March 31, 2016 (Japan GAAP) (Consolidated)

February 3, 2016

Company name: Mitsubishi Tanabe Pharma Corporation
 Stock exchange listings: Tokyo
 Securities code number: 4508
 URL: <http://www.mt-pharma.co.jp/>
 Representative: Name: Masayuki Mitsuka
 Title: President and Representative Director
 For further information, please contact: Name: Yoshifumi Mifune
 Title: General Manager, Corporate Communications Department
 Telephone: +81-6-6205-5211

Planned date of filing of quarterly securities report: February 9, 2016
 Planned date of start of dividend payments: —
 Provision of supplementary explanatory materials for quarterly results: Yes
 Quarterly results presentation: Yes (for institutional investors and securities analysts)

Notes: Amounts less than ¥1 million have been rounded.

Percentage changes in the list show change in comparison with the same period of the previous fiscal year.

1. Results for 3rd Quarter (April 1, 2015 to December 31, 2015)

(1) Consolidated Business Results

	Net sales		Operating income		Ordinary income	
	Millions of Yen	% change	Millions of Yen	% change	Millions of Yen	% change
3rd Quarter of Fiscal 2015	340,925	6.6	91,904	44.5	91,988	43.5
3rd Quarter of Fiscal 2014	319,777	(1.1)	63,588	14.5	64,088	10.9

	Net income attributable to shareholders of the Company		Net income attributable to shareholders of the Company per share	Net income attributable to shareholders of the Company per share (diluted)
	Millions of Yen	% change	Yen	Yen
3rd Quarter of Fiscal 2015	60,089	24.4	107.11	—
3rd Quarter of Fiscal 2014	48,294	10.1	86.09	—

(Note) Comprehensive income ¥56,773 million, 8.6% in 3rd quarter of fiscal 2015 (¥52,298 million, 9.6% in 3rd quarter of fiscal 2014)

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Millions of Yen	Millions of Yen	%
As of December 31, 2015	979,901	834,420	84.0
As of March 31, 2015	929,301	800,434	84.9

(Note) Shareholders' equity ¥823,555 million in 3rd quarter of fiscal 2015 (¥788,979 million in fiscal 2014)

2. Dividends

	Dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year-end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal 2014	—	20.00	—	22.00	42.00
Fiscal 2015	—	22.00	—		
Fiscal 2015 (forecasts)				22.00	44.00

(Note) Revisions to recently announced dividend forecasts: No

3. Forecasts for Fiscal 2015 (April 1, 2015 to March 31, 2016)

	Net sales		Operating income		Ordinary income	
	Millions of Yen	% change	Millions of Yen	% change	Millions of Yen	% change
Full year	429,000	3.3	92,000	37.0	91,000	34.5

	Net income attributable to shareholders of the Company		Net income attributable to shareholders of the Company per share
	Millions of Yen	% change	Yen
Full year	53,000	34.2	94.48

(Note) Revisions to recently announced consolidated earnings forecasts: Yes

※ Notes

(1) Significant change involving subsidiaries during the period: No

(Change in designated subsidiaries accompanying changes in the scope of consolidation)

(2) Application of special accounting methods in the preparation of quarterly financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and restatements

1. Change accompanying revision of accounting standards: Yes

2. Other changes: No

3. Change in accounting estimates: No

4. Restatements: No

(Note) For detailed information, please see "(1) Change in accounting policies, changes in accounting estimates, and restatements" under "2. Items Concerning Summary Data (The notes)" on page 4.

(4) Number of shares issued (common stock)

1. Number of shares issued at the end of the period (including treasury stock)

3rd Quarter of Fiscal 2015	561,417,916 shares	Fiscal 2014	561,417,916 shares
----------------------------	--------------------	-------------	--------------------

2. Number of treasury stock at the end of the period

3rd Quarter of Fiscal 2015	428,812 shares	Fiscal 2014	428,340 shares
----------------------------	----------------	-------------	----------------

3. Average number of shares during the period (cumulative total)

3rd Quarter of Fiscal 2015	560,989,314 shares	3rd Quarter of Fiscal 2014	560,990,643 shares
----------------------------	--------------------	----------------------------	--------------------

*Note regarding implementation of quarterly review procedures

At the time when this summary of 3rd quarter financial results was released, the review procedures for the quarterly financial statements were in progress in accordance with the Financial Instruments and Exchange Act.

*Explanation regarding the appropriate use of earnings forecasts and other matters of special note

(Note about forward-looking information)

In these materials, earnings forecasts and other statements about the future are forward-looking statements based on a number of assumptions and beliefs in light of the information available to management as of the date of release of the materials and are subject to risks and uncertainties. Accordingly, the Company cannot make promises to achieve such forecasts. Actual financial results may differ materially from these forecasts depending on a number of important factors.

For matters related to earnings forecasts, please see page 3.

(Methods of obtaining the supplementary materials and the content of the results presentation)

• Supplementary materials are included from page 12 of this document in section "4. Supplementary information."

• The Company plans to hold a results presentation (conference call) for institutional investors and securities analysts on February 3, 2016 (Wednesday).

The Company plans to make available on its website the content of the presentation (sound) and the materials used in the presentation immediately after the presentation is held.

Contents of supplement

1. Qualitative Information for 3rd Quarter of FY2015	1
(1)Explanation about results of operations	1
(2)Explanation about financial position	2
(3)Explanation about future prediction information of consolidated earnings forecasts	3
2. Items Concerning Summary Data(The notes)	4
(1)Changes in accounting policies, changes in accounting estimates, and restatements	4
3. Consolidated Financial Statements	5
(1)Consolidated Balance Sheets	5
(2)Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	7
Consolidated Statements of Income	7
Consolidated Statements of Comprehensive Income	8
(3)Consolidated Statements of Cash Flows	9
(4)Notes of Quarterly Consolidated Financial Statements	11
(Note regarding going concern assumption)	11
(Note regarding substantial change in shareholders' equity)	11
(Subsequent Event)	11
4. Supplementary information	12
(1)Consolidated Financial Indicators for 3rd Quarter of FY2015	12
(2)State of New Product Development	17

1. Qualitative Information for 3rd Quarter of FY 2015

(1) Explanation about results of operations

Consolidated operating results in the third quarter of the fiscal year ended March 31, 2016 (April 1, 2015 to December 31, 2015) were as follows.

(Millions of yen)

	3 rd quarter of FY 2014	3 rd quarter of FY 2015	Increase/ Decrease	% change
Net sales	319,777	340,925	21,148	6.6
Cost of sales	128,025	120,844	(7,181)	(5.6)
Cost of sales ratio	40.0%	35.4%		
Gross profit	191,752	220,081	28,329	14.8
SG&A expenses	128,164	128,177	13	0.0
Operating income	63,588	91,904	28,316	44.5
Non-operating income/loss	500	84	(416)	
Ordinary income	64,088	91,988	27,900	43.5
Extraordinary income/loss	5,788	(3,254)	(9,042)	
Net income attributable to shareholders of the Company	48,294	60,089	11,795	24.4

【Net sales】

Net sales increased by 6.6%, or ¥21.1 billion, year-on-year, to ¥340.9 billion.

(Millions of yen)

	3 rd quarter of FY 2014	3 rd quarter of FY 2015	Increase/ Decrease	% change
Pharmaceuticals	319,443	340,640	21,197	6.6
Domestic ethical drugs	252,003	240,653	(11,350)	(4.5)
Overseas ethical drugs	16,793	19,792	2,999	17.9
OTC products	3,180	3,053	(127)	(4.0)
Others in Pharmaceuticals	47,467	77,142	29,675	62.5
Others	334	285	(49)	(14.7)

In the pharmaceuticals segment, net sales were ¥340.6 billion, up 6.6%, or ¥21.1 billion, year-on-year.

- Domestic sales of ethical drugs decreased by 4.5%, year-on-year, to ¥240.6 billion due to the termination of the sales alliance of the plasma fractionation products in March 2015.
- Sales of others in pharmaceuticals increased by 62.5%, year-on-year, to ¥77.1 billion due to the following reasons:
 - Increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis
 - Increase in royalty revenue from INVOKANA and the fixed dose combination with metformin (IR), for the treatment of type2 diabetes mellitus, licensed to Janssen Pharmaceuticals
 - Receipt of the upfront payment accompanying the licence agreement with Biogen related to MT-1303, a therapeutic agent for autoimmune diseases
 - Receipt of the lump-sum payment accompanying a patent and know-how transfer agreement with Amgen and Dezima regarding TA-8995, a treatment agent for dyslipidemia (CETP inhibitor)

【Operating income】

Operating income increased by 44.5%, or ¥28.3 billion, year-on-year, to ¥91.9 billion.

- The cost of sales ratio improved by 4.6 percentage points, to 35.4% due to the ending of the sales alliance of the plasma fractionation products, the increase in royalty revenue and the receipt of the upfront payments. Gross profit increased by ¥28.3 billion, year-on-year, to ¥220.0 billion.
- R&D expenses increased, on the other hand, sales promotion expenses decreased. Consequently, total SG&A expenses were ¥128.1 billion and remained at the same level in compared with the same period of the previous fiscal year. R&D expenses were ¥50.2 billion, accounting for 14.7% of net sales.

【Ordinary income and net income attributable to shareholders of the Company】

Ordinary income was up 43.5%, or ¥27.9 billion, year-on-year, to ¥91.9 billion, and net income attributable to shareholders of the Company was up 24.4%, or ¥11.7 billion, year-on-year, to ¥60.0 billion.

- Non-operating income/loss was down ¥0.4 billion, year-on-year, due to the recording of foreign exchange loss of ¥0.4 billion.
- Extraordinary income was ¥12.9 billion in compared with ¥13.5 billion in the same period of the previous fiscal year, due to the recording of gain on sales of property, plant and equipment, and gain on sales of investment in securities in both year.
- Extraordinary loss was ¥16.1 billion in compared with ¥7.7 billion in the same period of the previous fiscal year, due to the recording of restructuring expenses and loss on impairment of fixed assets in both year.

【Comprehensive income】

Net income was ¥58.5 billion. In other comprehensive income, translation adjustments decreased, on the other hand, unrealized holding gains on securities increased. As a result, comprehensive income was ¥56.7 billion. Comprehensive income attributable to shareholders of the Company was ¥59.2 billion.

(2) Explanation about financial position**【Balance sheets】**

(Millions of yen)

	End of FY 2014 (As of March 31, 2015)	End of 3 rd quarter of FY 2015 (As of December 31, 2015)	Increase/ Decrease
Current assets	603,649	681,255	77,606
Fixed assets	325,652	298,646	(27,006)
Total assets	929,301	979,901	50,600
Liabilities	128,867	145,481	16,614
Net assets	800,434	834,420	33,986
Total liabilities and net assets	929,301	979,901	50,600

Total assets at the end of the third quarter were ¥979.9 billion, a increase of ¥50.6 billion from the end of the previous fiscal year.

Major factors causing changes in the balance sheet in comparison with the previous year-end were as follows.

- Cash and time deposits increased. Consequently, total current assets were up ¥77.6 billion, to ¥681.2 billion.
- Total fixed assets were down ¥27.0 billion from the previous fiscal year-end, to ¥298.6 billion, due to the decrease of investment in securities and intangible fixed assets.
- Accounts payable - other and notes and accounts payable - trade increased. Consequently, total liabilities were up ¥16.6 billion, to ¥145.4 billion.
- Total net assets were up by ¥33.9 billion, to ¥834.4 billion due to the increase of retained earnings. The equity ratio was 84.0%, compared with 84.9% as of the previous fiscal year-end.

【Cash flows】

(Millions of yen)

	3 rd quarter of FY 2014	3 rd quarter of FY 2015	Increase/ Decrease
Operating activities	30,907	59,372	28,465
Investing activities	(15,348)	47,511	62,859
Financing activities	(22,383)	(22,967)	(584)
Change in cash and cash equivalents	(4,568)	83,270	87,838
Cash and cash equivalents at beginning of year	84,957	73,337	(11,620)
Cash and cash equivalents at end of period	80,389	156,607	76,218

Net increase in cash and cash equivalents was ¥83.2 billion, and the balance of cash and cash equivalents at the end of the period under review was ¥156.6 billion.

- Net cash provided by operating activities was ¥59.3 billion. Cash outflows included income taxes paid, while cash inflows including income before income taxes and non-controlling interests exceeded cash outflows.
- Net cash provided by investing activities was ¥47.5 billion. Cash outflows included purchase of property, plant and equipment and of marketable securities, and increase in time deposits, while cash inflows including proceeds from sales of investment in securities and redemption of marketable securities, and decrease in time deposits exceeded cash outflows.
- Net cash used in financing activities was ¥22.9 billion, due in part to dividends paid.

(3) Explanation about future prediction information of consolidated earnings forecasts

Based on the consolidated operating results of the third quarter and the current sales situation, the Company revised the full-year earnings forecasts for the fiscal year ended March 31, 2016, which were announced on September 30, 2015.

Regarding net sales, the Company revised upward the forecasts of net sales due to strong sales of vaccines in domestic ethical drug operations and the increase in royalty revenue.

Concerning profits, the Company anticipates that both operating income and ordinary income will exceed the previously announced forecasts due to the decrease in SG&A expenses, mainly R&D expenses, in addition to the factors mentioned in net sales.

The Company expects that net income attributable to shareholders of the Company will also result in exceeding the last forecasts, due to gain on sales of investment in securities of extraordinary income, even though additional extraordinary losses accompanying the acceleration of the ongoing structural reforms are planned in the fourth quarter.

Therefore, taking those factors into consideration, the Company revised upward the forecasts of each profits.

Revision to consolidated financial forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016)

(Millions of yen)

	Net Sales	Operating income	Ordinary income	Net income attributable to shareholders of the Company	Net income attributable to shareholders of the Company per share (Yen)
Previous forecast (A)	418,000	82,000	81,000	46,000	82.00
Revised forecast (B)	429,000	92,000	91,000	53,000	94.48
Difference (B-A)	11,000	10,000	10,000	7,000	—
% change	2.6	12.2	12.3	15.2	—
(Reference) Results in the same period of the previous fiscal year	415,124	67,133	67,654	39,502	70.41

The above financial forecasts are forward-looking statements based on a number of assumptions and beliefs in light of the information available to management as of the date of release of the materials. Accordingly, actual results may differ materially from these forecasts for various reasons.

2. Items Concerning Summary Data (The notes)

(1) Changes in accounting policies, changes in accounting estimates, and restatements

(The application of the accounting standards for business combinations)

From the first quarter of the fiscal year, the Company has applied the “Revised Accounting Standard for Business Combinations” (ASBJ Statement No. 21 on September 13, 2013), “Revised Accounting Standard for Consolidated Financial Statements” (ASBJ Statement No. 22 on September 13, 2013) and “Revised Accounting Standard for Business Divestitures” (ASBJ Statement No. 7 on September 13, 2013). The Company has revised the method to record the change in the Company’s ownership interests in the subsidiaries subject to ongoing control as capital surplus, and to recognize acquisition-related costs as expenses in the fiscal year incurred. With respect to the business combination carried out after the beginning of the current fiscal year, the Company has revised the allocation of acquisition costs based on provisional accounting treatment, reflecting these costs in the quarterly consolidated financial statements for the fiscal year in which the business combination occurred. In addition, the Company has revised the presentation of net income and changed the presentation from “Minority interests” to “Non-controlling interests”.

To reflect these changes in presentation method, the consolidated financial statements for the previous fiscal year have been subject to these arrangements.

In the quarterly consolidated statements of cash flows of the third quarter of the fiscal year under review, cash flow from sales or purchases of shares of subsidiaries without the change in the scope of consolidation is listed in “Cash flows from financing activities”. Also, the expenses related to the purchases of shares of subsidiaries accompanying changes in the scope of consolidation, or the cash flow related to the expenses resulting from sales or purchases of shares of subsidiaries without the change in the scope of consolidation are listed in “Cash flows from operating activities”.

Regarding the application of the Accounting Standard for Business Combinations, the Company has applied the transitional treatment provided in Paragraph 58-2 (4) of the Revised Accounting Standard for Business Combinations, Paragraph 44-5 (4) of the Revised Accounting Standard for Consolidated Financial Statements, and Paragraph 57-4 (4) of the Revised Accounting Standard for Business Divestitures from the beginning of the fiscal year and will continue to apply this treatment going forward. The application of the revised accounting standards does not affect the Company’s quarterly consolidated financial statements during the third quarter of the fiscal year under review.

3. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2015	As of December 31, 2015
	Amount	Amount
Assets		
Current assets		
Cash and time deposits	50,203	156,177
Notes and accounts receivable - trade	130,331	155,735
Marketable securities	118,805	73,502
Merchandise and finished goods	63,566	49,071
Work in process	582	400
Raw materials and supplies	20,943	21,320
Deposits	192,758	193,062
Deferred tax assets	8,319	12,260
Other	18,186	19,770
Less allowance for doubtful receivables	(44)	(42)
Total current assets	603,649	681,255
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	34,480	33,827
Machinery, equipment and vehicles, net	11,904	12,062
Tools, furniture and fixtures, net	6,045	5,874
Land	34,689	33,896
Leased equipment, net	782	889
Construction in progress	4,597	5,655
Total property, plant and equipment	92,497	92,203
Intangible fixed assets		
Goodwill	81,517	73,160
Other	35,402	32,375
Total intangible fixed assets	116,919	105,535
Investments and other assets		
Investment in securities	76,328	59,512
Deferred tax assets	763	436
Net defined benefit asset	15,730	19,307
Other	23,417	21,654
Less allowance for doubtful receivables	(2)	(1)
Total investments and other assets	116,236	100,908
Total fixed assets	325,652	298,646
Total assets	929,301	979,901

(Millions of yen)

	As of March 31, 2015	As of December 31, 2015
	Amount	Amount
Liabilities		
Current liabilities		
Notes and accounts payable - trade	34,620	42,965
Current maturities of long-term debt	132	127
Accounts payable - other	25,386	37,615
Income taxes payable	19,758	20,252
Reserve for employees' bonuses	9,957	5,484
Other reserve	138	1,847
Other	15,408	14,470
Total current liabilities	105,399	122,760
Long-term liabilities		
Long-term debt, less current maturities	894	760
Deferred tax liabilities	9,776	9,982
Reserve for health management allowances for HIV compensation	1,700	1,700
Reserve for health management allowances for SMON compensation	2,731	2,408
Reserve for HCV litigation	2,036	1,668
Net defined benefit liability	2,456	2,441
Other	3,875	3,762
Total long-term liabilities	23,468	22,721
Total liabilities	128,867	145,481
Net assets		
Shareholders' equity		
Common stock	50,000	50,000
Capital surplus	451,186	451,186
Retained earnings	275,325	310,729
Treasury stock, at cost	(493)	(494)
Total shareholders' equity	776,018	811,421
Accumulated other comprehensive income		
Unrealized holding gains (losses) on securities	14,929	15,976
Deferred gains (losses) on hedges	105	0
Translation adjustments	105	(2,083)
Remeasurements of defined benefit plans	(2,178)	(1,759)
Total accumulated other comprehensive income	12,961	12,134
Non-controlling interests	11,455	10,865
Total net assets	800,434	834,420
Total liabilities and net assets	929,301	979,901

**(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)**

(Millions of yen)

	April 1, 2014 - December 31, 2014	April 1, 2015 - December 31, 2015
	Amount	Amount
Net sales	319,777	340,925
Cost of sales	128,025	120,844
Gross profit	191,752	220,081
Selling, general and administrative expenses		
Advertising expenses	2,551	2,580
Sales promotion expenses	7,138	5,901
Salaries and allowances	24,830	25,063
Provision for bonuses	2,966	3,114
Retirement benefit expenses	979	346
Depreciation and amortization	1,251	1,386
Research and development expenses	48,085	50,260
Amortization of goodwill	8,095	7,881
Other	32,269	31,646
Total selling, general and administrative expenses	128,164	128,177
Operating income	63,588	91,904
Non-operating income		
Interest income	1,187	1,178
Dividend income	771	1,156
Other	815	637
Total non-operating income	2,773	2,971
Non-operating expense		
Interest expense	142	152
Donations	846	939
Foreign exchange loss	—	478
Other	1,285	1,318
Total non-operating expense	2,273	2,887
Ordinary income	64,088	91,988
Extraordinary income		
Gain on sales of property, plant and equipment	11,924	707
Gain on sales of investment in securities	1,069	12,238
Gain on sales of shares of subsidiaries and affiliates	560	—
Total extraordinary income	13,553	12,945
Extraordinary loss		
Loss on impairment of fixed assets	965	694
Restructuring expenses	6,562	15,505
Loss on valuation of investment in securities	130	—
Other	108	—
Total extraordinary loss	7,765	16,199
Income before income taxes and non-controlling interests	69,876	88,734
Income taxes-current	22,101	33,622
Income taxes-deferred	646	(3,444)
Total income taxes	22,747	30,178
Net income	47,129	58,556
Net income (loss) attributable to non-controlling interests	(1,165)	(1,533)
Net income attributable to shareholders of the Company	48,294	60,089

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

	April 1, 2014 - December 31, 2014	April 1, 2015 - December 31, 2015
	Amount	Amount
Net income	47,129	58,556
Other comprehensive income		
Unrealized holding gains (losses) on securities	788	1,047
Deferred gains (losses) on hedges	(394)	(105)
Translation adjustments	3,960	(3,121)
Remeasurements of defined benefit plans, net of tax	791	419
Other comprehensive income (loss) of equity method companies attributable to the Company	24	(23)
Total other comprehensive income (loss)	5,169	(1,783)
Comprehensive income	52,298	56,773
Comprehensive income (loss) attributable to:		
Shareholders of the Company	53,205	59,262
Non-controlling interests	(907)	(2,489)

(3) Consolidated Statements of Cash Flows

(Millions of yen)

	April 1, 2014 - December 31, 2014	April 1, 2015 - December 31, 2015
Cash flows from operating activities:		
Income before income taxes and non-controlling interests	69,876	88,734
Depreciation and amortization	6,656	6,636
Loss on impairment of fixed assets	965	694
Amortization of goodwill	8,095	7,881
Decrease (increase) in net defined benefit asset	(2,984)	(3,577)
Increase (decrease) in reserve for HCV litigation	(410)	(368)
Increase (decrease) in reserve for health management allowances for SMON compensation	(316)	(323)
Interest and dividend income	(1,958)	(2,334)
Loss (gain) on sales of shares of subsidiaries and affiliates	(560)	—
Loss (gain) on sale of property, plant and equipment	(11,786)	(581)
Restructuring expenses	6,562	15,505
Loss (gain) on sale of investment in securities	(1,069)	(12,238)
Decrease (increase) in notes and accounts receivable - trade	(29,621)	(25,561)
Decrease (increase) in inventories	6,286	11,359
Increase (decrease) in notes and accounts payable - trade	(2,839)	8,437
Increase (decrease) in accounts payable - other	1,116	(1,636)
Other, net	1,003	(1,910)
Subtotal	49,016	90,718
Interest and dividends received	1,908	2,319
Interest paid	(163)	(152)
Income taxes paid	(19,854)	(33,513)
Net cash provided by (used in) operating activities	30,907	59,372
Cash flows from investing activities:		
Purchase of marketable securities	(75,300)	(89,500)
Proceeds from sales and redemption of marketable securities	53,011	122,800
Increase in time deposits	(1,054)	(32,555)
Decrease in time deposits	4,753	24,892
Increase in deposits	(10,471)	(304)
Purchase of property, plant and equipment	(6,468)	(9,295)
Proceeds from sales of property, plant and equipment	11,070	2,757
Purchase of intangible fixed assets	(1,096)	(944)
Proceeds from sales and redemption of investment in securities	1,297	26,537
Proceeds from sales of shares of subsidiaries and affiliates	7,600	—
Proceeds from company split	—	3,323
Proceeds from sales of shares of subsidiaries accompanying changes in the scope of consolidation	1,467	—
Other, net	(157)	(200)
Net cash provided by (used in) investing activities	(15,348)	47,511

	April 1, 2014 - December 31, 2014	April 1, 2015 - December 31, 2015
Cash flows from financing activities:		
Increase (decrease) in short-term debt, net	(973)	—
Cash dividends paid	(22,439)	(24,684)
Cash dividends paid to non-controlling shareholders	(570)	(75)
Proceeds from share issuance to non-controlling shareholders	1,698	1,973
Other, net	(99)	(181)
Net cash provided by (used in) financing activities	(22,383)	(22,967)
Effect of exchange rate change on cash and cash equivalents	2,256	(646)
Net increase (decrease) in cash and cash equivalents	(4,568)	83,270
Cash and cash equivalents at beginning of the period	84,957	73,337
Cash and cash equivalents at end of the period	80,389	156,607

(4) Notes of Quarterly Consolidated Financial Statements

(Note regarding going concern assumption)

Not applicable.

(Note regarding substantial change in shareholders' equity)

Not applicable.

(Subsequent Event)

Not applicable.

4. Supplementary Information

(1) Consolidated Financial Indicators for 3rd Quarter of FY2015

i. PL (Cumulative 3rd Quarter)

[Billions of yen]

	Cumulative Q3/FY2015		Cumulative Q3/FY2014		Year-on-year		Comparison to Full-year Forecasts			Notes [year-on-year comparison]
	Actual	Ratio to sales	Actual	Ratio to sales	Increase (Decrease)	Change	Previous Forecasts ^{*1}	Revise Forecasts ^{*2}	Achieved ^{*2}	
Net sales	340.9	100.0	319.8	100.0	21.1	6.6	418.0	429.0	79.5	
Domestic	245.9	72.1	263.6	82.4	(17.7)	(6.7)	303.4	-	81.1	Average exchange rate Q3 FY2015: 1US \$ = ¥ 121.63 Q3 FY2014: 1US \$ = ¥ 107.75
Overseas	95.0	27.9	56.2	17.6	38.8	69.1	114.6	-	82.9	
Cost of sales	120.8	35.4	128.0	40.0	(7.2)	(5.6)	150.0	155.0	78.0	Improvement due to the ending of the sales alliance of the plasma fractionation products, increase of royalty income, etc.
Gross profit	220.1	64.6	191.8	60.0	28.3	14.8	268.0	274.0	80.3	
SG&A expenses	128.2	37.6	128.2	40.1	0.0	0.0	186.0	182.0	70.4	
R&D expenses	50.3	14.7	48.1	15.0	2.2	4.5	76.0	74.0	67.9	
Non-R&D expenses	77.9	22.9	80.1	25.0	(2.2)	(2.7)	110.0	108.0	72.1	
Labor cost	34.8	10.2	34.8	10.9	0.0	(0.1)	47.0	47.0	74.0	
Amortization of goodwill	7.9	2.3	8.1	2.5	(0.2)	(2.6)	10.5	10.5	75.1	
Others	35.3	10.3	37.2	11.6	(1.9)	(5.1)	52.5	50.5	69.9	
Operating income	91.9	27.0	63.6	19.9	28.3	44.5	82.0	92.0	99.9	
Non-operating income	3.0		2.8		0.2					
Interest income	1.2		1.2		0.0					
Dividend income	1.2		0.8		0.4					
Others	0.6		0.8		(0.2)					
Non-operating expenses	2.9		2.3		0.6					
Interest expense	0.2		0.1		0.0					
Donations	0.9		0.8		0.1					
Foregin exchange loss	0.5		-		0.5					
Others	1.3		1.3		0.0					
Ordinary income	92.0	27.0	64.1	20.0	27.9	43.5	81.0	91.0	101.1	
Extraordinarily income	12.9		13.6		(0.6)		-	-	-	
Gain on sales of property, plant and equipment	0.7		11.9		(11.2)					FY2015: Toda dormitory, Hiranomachi building No.1 FY2014: a vacant lot of the former Nihonbashi building
Gain on sales of investments in securities	12.2		1.1		11.2					
Gain on sales of shares of subsidiaries and affiliates	-		0.6		(0.6)					FY2014: Sales of shares of API Corporation and CMIC CMO, Ashikaga
Extraordinary losses	16.2		7.8		8.4		-	-	-	
Restructuring expenses	15.5		6.6		8.9					Including 15.3 billion yen of the premium retirement payments and outplacement costs
Impairment loss	0.7		1.0		(0.3)					FY2015: Research building No.2 at Kashima FY2014: Toda dormitory, etc.
Loss on valuation of investment in securities	-		0.1		(0.1)					
Others	-		0.1		(0.1)					
Net income attributable to shareholders of the Company	60.1	17.6	48.3	15.1	11.8	24.4	46.0	53.0	113.4	
Total labor cost	58.3	17.1	59.9	18.7	(1.6)	(2.6)	78.5	78.5	74.3	

*1: Published forecasts announced on October 30, 2015 in the financial results of Q2 FY2015.

*2: The Company revised the financial forecasts for FY2015 on February 3, 2016, however does not revise sales breakdown. Achieved % of domestic sales and overseas sales are calculated using the previous forecasts and the others are calculated using the revised forecasts.

ii. Sales of Main Products (Cumulative 3rd Quarter)

[Billions of yen]

	Q3 FY2015 Apr.-Dec.	Y-on-Y			Comparison to Full-year Forecasts		
		Q3 FY2014 Apr.-Dec.	Increase (Decrease)	Change %	Previous Forecasts ^{*1}	Revised forecasts ^{*2}	Achieved % ^{*2}
Ethical drugs	337.6	316.3	21.3	6.7	413.5	-	81.6
Ethical drugs domestic sales	240.7	252.0	(11.4)	(4.5)	296.6	-	81.1
Remicade	54.0	54.5	(0.5)	(0.9)	67.7	-	79.8
Ceredist	11.4	12.3	(0.8)	(6.7)	13.7	-	83.7
Talion	11.2	10.3	0.9	8.3	16.9	-	66.3
Tenelia (previous scheme) ^{*3}	3.7	4.6	(0.9)	(19.9)	3.7	-	99.7
Tenelia (new scheme) ^{*3}	7.3	Undisclosed	-	-	9.9	-	73.5
Maintate	10.7	10.9	(0.3)	(2.3)	13.2	-	80.8
Simponi	9.8	8.0	1.8	23.0	12.6	-	77.8
Lexapro	7.4	6.1	1.3	20.8	10.4	-	71.1
Kremezin	7.4	8.2	(0.9)	(10.3)	9.1	-	81.6
Urso	6.6	7.8	(1.2)	(15.0)	8.4	-	78.9
Depas	5.7	6.3	(0.5)	(8.6)	7.0	-	82.1
Radicut	5.6	5.9	(0.3)	(4.5)	6.2	-	90.4
Anplag	5.2	6.6	(1.3)	(20.4)	6.4	-	82.6
BIKEN products [vaccines]	31.5	25.9	5.7	21.8	32.6	-	96.5
Influenza	12.1	8.2	3.8	46.8	11.2	-	107.6
Tetrabik	7.2	5.7	1.6	27.4	7.4	-	97.9
Tanabe Seiyaku Hanbai products ^{*4}	10.6	10.3	0.2	2.3	14.0	-	75.5
Ethical drugs overseas sales	19.8	16.8	3.0	17.9	25.2	-	78.4
Herbesser	4.7	4.9	(0.2)	(4.4)	6.8	-	69.1
Argatroban (Novastan)	2.2	1.7	0.4	24.4	2.8	-	77.6
Tanatril	1.2	1.4	(0.2)	(12.8)	1.7	-	72.7
Contracted manufacturing products ^{*5}	1.5	2.6	(1.1)	(42.4)	2.1	-	72.5
Royalty income, etc.	75.7	44.9	30.8	68.6	89.6	-	84.4
Royalty from Gilenya	39.9	32.5	7.4	22.7	Undisclosed	-	-
Royalty from INVOKANA	16.7	6.1	10.6	172.5	Undisclosed	-	-
OTC products	3.1	3.2	(0.1)	(4.0)	4.1	-	74.3
Total sales	340.9	319.8	21.1	6.6	418.0	429.0	79.5

*1: Published forecasts announced on October 30, 2015 in the financial results of Q2 FY2015.

*2: The Company revised the financial forecasts for FY2015 on February 3, 2016, however does not revised the forecasts of sales breakdown including sales of each product. Achieved % of "total sales" is calculated using the revised forecasts and the others are calculated using the previous forecasts.

*3: The scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company discloses total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*4: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from the Company.

*5: Active pharmaceutical ingredients and others ordered by outside companies.

iii. Sales of Main Products (3rd Quarter)

[Billions of yen]

	Q3 FY2015 Oct.-Dec.	Y-on-Y			Comparison to Full-year Forecasts		
		Q3 FY2014 Oct.-Dec.	Increase (Decrease)	Change %	Previous Forecasts ^{*1}	Revised forecasts ^{*2}	Achieved % ^{*2}
Ethical drugs	138.1	119.8	18.4	15.3	214.1	-	64.5
Ethical drugs domestic sales	93.3	96.8	(3.5)	(3.6)	149.2	-	62.5
Remicade	19.5	19.3	0.2	1.2	33.2	-	58.8
Ceredist	4.1	4.4	(0.3)	(6.8)	6.3	-	64.6
Talion	4.8	4.3	0.5	11.8	10.4	-	45.6
Tenelia (new scheme)	4.3	Undisclosed	-	-	7.0	-	62.3
Maintate	3.8	3.8	0.0	(0.9)	6.3	-	59.7
Simponi	3.6	2.9	0.7	23.9	6.4	-	56.5
Lexapro	3.0	2.7	0.3	11.1	6.1	-	50.1
Kremezin	2.6	2.8	(0.2)	(8.8)	4.2	-	60.6
Urso	2.2	2.7	(0.5)	(17.9)	4.0	-	55.6
Depas	2.0	2.2	(0.2)	(7.5)	3.3	-	61.8
Radicut	2.2	2.1	0.1	4.8	2.8	-	78.7
Anplag	1.8	2.2	(0.5)	(20.3)	2.9	-	61.6
BIKEN products [vaccines]	17.0	14.8	2.3	15.2	18.1	-	93.8
Influenza	9.3	7.3	2.0	26.7	8.4	-	110.1
Tetrabik	3.6	2.1	1.5	69.2	3.8	-	95.8
Tanabe Seiyaku Hanbai products ^{*4}	4.0	3.9	0.1	1.9	7.4	-	53.6
Ethical drugs overseas sales	5.5	5.5	0.1	1.4	11.0	-	50.4
Herbesser	1.6	1.4	0.1	9.9	3.7	-	43.1
Argatroban (Novastan)	0.6	0.5	0.1	22.2	1.2	-	48.7
Tanatril	0.4	0.4	0.0	1.8	0.9	-	46.5
Contracted manufacturing products ^{*5}	0.4	0.5	(0.1)	(13.9)	1.0	-	43.7
Royalty income, etc.	38.9	17.0	21.8	128.3	52.9	-	73.5
Royalty from Gilenya	14.0	13.7	0.4	2.6	Undisclosed	-	-
Royalty from INVOKANA	6.8	Undisclosed	-	-	Undisclosed	-	-
OTC products	1.0	1.0	0.0	(4.3)	2.0	-	47.5
Total sales	139.2	120.9	18.3	15.1	216.3	227.3	61.2

*1: Published forecasts announced on October 30, 2015 in the financial results of Q2 FY2015.

*2: The Company revised the financial forecasts for FY2015 on February 3, 2016, however does not revised the forecasts of sales breakdown including sales of each product. Achieved % of "total sales" is calculated using the revised forecasts and the others are calculated using the previous forecasts.

*3: The scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company discloses total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*4: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from the Company.

*5: Active pharmaceutical ingredients and others ordered by outside companies.

iv. Quarterly Trend (Profit and Loss)

[Billions of yen]

	FY2014					FY2015			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full year Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Full year forecasts*
Net sales	94.6 22.8%	104.3 25.1%	120.9 29.1%	95.3 23.0%	415.1 100.0%	98.5 23.0%	103.2 24.1%	139.2 32.4%	429.0 100.0%
Domestic	79.8 23.7%	85.3 25.3%	98.6 29.2%	73.6 21.8%	337.2 100.0%	76.3 25.1%	74.6 24.6%	95.0 31.3%	<i>303.4</i> 100.0%
Overseas	14.8 19.0%	19.1 24.5%	22.3 28.7%	21.7 27.9%	77.9 100.0%	22.2 19.4%	28.6 25.0%	44.2 38.5%	<i>114.6</i> 100.0%
Cost of sales	39.2	39.0	49.8	41.6	169.6	35.5	37.6	47.7	155.0
Sales cost ratio	41.4%	37.4%	41.2%	43.6%	40.9%	36.1%	36.5%	34.2%	36.1%
Gross profit	55.4 22.6%	65.3 26.6%	71.0 28.9%	53.8 21.9%	245.5 100.0%	63.0 23.0%	65.6 23.9%	91.5 33.4%	274.0 100.0%
SG&A expenses	41.7 23.4%	44.1 24.7%	42.4 23.8%	50.2 28.2%	178.4 100.0%	40.2 22.1%	44.8 24.6%	43.1 23.7%	182.0 100.0%
R&D expenses	16.3 23.5%	15.6 22.4%	16.2 23.2%	21.5 30.9%	69.6 100.0%	15.5 20.9%	17.8 24.1%	17.0 23.0%	74.0 100.0%
Non-R&D expenses	25.3 23.3%	28.5 26.2%	26.3 24.1%	28.7 26.4%	108.8 100.0%	24.8 22.9%	27.0 25.0%	26.1 24.2%	108.0 100.0%
Labor costs	11.1 23.8%	11.9 25.5%	11.8 25.2%	12.0 25.6%	46.8 100.0%	11.2 23.8%	11.8 25.1%	11.8 25.0%	47.0 100.0%
Amortization of goodwill	2.7 24.7%	2.7 24.7%	2.7 24.7%	2.8 25.8%	10.9 100.0%	2.6 25.1%	2.6 25.0%	2.6 25.0%	10.5 100.0%
Others	11.5 22.6%	13.9 27.1%	11.8 23.1%	13.9 27.2%	51.1 100.0%	10.9 21.7%	12.6 24.9%	11.8 23.3%	50.5 100.0%
Operating income	13.7 20.4%	21.3 31.7%	28.6 42.7%	3.5 5.3%	67.1 100.0%	22.7 24.7%	20.8 22.6%	48.4 52.6%	92.0 100.0%
Ordinary income	14.6 21.5%	20.9 30.9%	28.6 42.3%	3.6 5.3%	67.7 100.0%	22.6 24.9%	20.7 22.7%	48.7 53.5%	91.0 100.0%
Net income attributable to shareholders of the Company	9.6 24.3%	22.9 58.1%	15.8 39.9%	(8.8) (22.3%)	39.5 100.0%	14.9 28.1%	14.3 26.9%	30.9 58.4%	53.0 100.0%

The each figure (excluding "cost of sales") in the lower displays the progress rate.

*: The Company revised the financial forecasts for FY2015 on February 3, 2016, however does not revise sales breakdown. Full year forecasts of domestic sales and overseas sales in the above table, which are indicated in italics, have been announced on October 30, 2015 in the financial results of Q2 FY2015. Other items were revised on February 3, 2016.

v. Quarterly Trend (Sales of Main Products)

[Billions of yen]

	FY2014					FY2015			
	Q1	Q2	Q3	Q4	Full year	Q1	Q2	Q3	Full year
	Apr. to Jun.	Jul. to Sep.	Oct. to Dec.	Jan. to Mar.	actual	Apr. to Jun.	Jul. to Sep.	Oct. to Dec.	forecasts ^{*1}
Ethical drugs	93.2	103.3	119.8	94.4	410.7	97.2	102.2	138.1	413.5
	22.7%	25.1%	29.2%	23.0%	100.0%	23.5%	24.7%	33.4%	100.0%
Ethical drugs domestic sales	77.5	77.7	96.8	71.9	323.9	74.3	73.1	93.3	296.6
	23.9%	24.0%	29.9%	22.2%	100.0%	25.0%	24.6%	31.5%	100.0%
Remicade	17.3	17.9	19.3	16.1	70.6	16.9	17.6	19.5	67.7
	24.6%	25.3%	27.3%	22.8%	100.0%	24.9%	26.1%	28.8%	100.0%
Talion	3.3	2.8	4.3	5.7	16.0	3.6	2.9	4.8	16.9
	20.3%	17.7%	26.6%	35.4%	100.0%	21.1%	17.0%	28.2%	100.0%
Ceredist	4.1	3.8	4.4	3.4	15.7	3.9	3.5	4.1	13.7
	26.4%	24.0%	27.9%	21.7%	100.0%	28.4%	25.5%	29.8%	100.0%
Maintate	3.8	3.4	3.8	3.2	14.1	3.7	3.2	3.8	13.2
	26.7%	23.9%	26.8%	22.6%	100.0%	27.9%	24.5%	28.4%	100.0%
Simponi	2.5	2.6	2.9	2.5	10.5	3.0	3.2	3.6	12.6
	23.5%	24.6%	27.9%	23.9%	100.0%	24.0%	25.1%	28.8%	100.0%
Tenelia (previous scheme) ^{*2}	1.1	1.6	1.9	1.7	6.2	2.0	1.7	(0.1)	3.7
	17.9%	24.9%	30.6%	26.5%	100.0%	55.4%	46.3%	(2.1%)	100.0%
Tenelia (new scheme) ^{*2}	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	4.3	9.9
	-	-	-	-	-	-	-	43.8%	100.0%
Lexapro	1.7	1.7	2.7	1.8	8.0	2.1	2.2	3.0	10.4
	21.1%	21.7%	34.3%	22.9%	100.0%	20.5%	21.5%	29.1%	100.0%
Kremezin	2.8	2.6	2.8	2.3	10.5	2.5	2.3	2.6	9.1
	26.6%	24.9%	26.8%	21.8%	100.0%	27.8%	25.4%	28.4%	100.0%
Urso	2.7	2.4	2.7	2.2	10.0	2.4	2.0	2.2	8.4
	26.7%	24.2%	27.0%	22.1%	100.0%	28.3%	24.2%	26.4%	100.0%
Depas	2.1	2.0	2.2	1.8	8.1	1.9	1.8	2.0	7.0
	25.9%	24.9%	27.1%	22.2%	100.0%	27.8%	25.4%	28.9%	100.0%
Anplag	2.4	2.0	2.2	1.7	8.3	1.9	1.6	1.8	6.4
	28.7%	23.9%	27.0%	20.5%	100.0%	30.1%	24.4%	28.0%	100.0%
Radicut	2.0	1.8	2.1	1.5	7.4	1.7	1.8	2.2	6.2
	26.7%	24.7%	28.3%	20.3%	100.0%	26.7%	28.5%	35.3%	100.0%
BIKEN products [vaccines]	4.9	6.2	14.8	4.4	30.3	6.3	8.2	17.0	32.6
	16.2%	20.4%	48.8%	14.5%	100.0%	19.3%	25.1%	52.1%	100.0%
Influenza	(0.1)	0.9	7.3	(0.8)	7.4	0.0	2.8	9.3	11.2
	(0.7%)	12.7%	99.3%	(11.3%)	100.0%	(0.3%)	25.0%	82.9%	100.0%
Tetrabik	1.8	1.8	2.1	1.8	7.5	1.9	1.7	3.6	7.4
	23.6%	23.7%	28.2%	24.4%	100.0%	26.1%	23.3%	48.5%	100.0%
Varicella vaccine	0.6	1.3	3.5	1.7	7.2	1.8	1.5	1.6	6.1
	8.7%	18.2%	48.8%	24.3%	100.0%	29.2%	25.2%	26.7%	100.0%
Tanabe Seiyaku Hanbai products ^{*3}	3.4	3.1	3.9	3.3	13.6	3.4	3.2	4.0	14.0
	24.8%	22.5%	28.6%	24.0%	100.0%	24.3%	22.8%	28.3%	100.0%
Ethical drugs overseas sales	5.3	6.0	5.5	6.2	23.0	6.2	8.1	5.5	25.2
	23.0%	26.3%	23.7%	27.1%	100.0%	24.5%	32.0%	21.9%	100.0%
Herbesser	1.6	1.9	1.4	1.6	6.5	1.5	1.6	1.6	6.8
	24.4%	29.1%	22.3%	24.2%	100.0%	22.1%	23.6%	23.4%	100.0%
Argatroban (Novastan)	0.7	0.6	0.5	0.4	2.1	0.5	1.1	0.6	2.8
	32.5%	26.5%	22.9%	18.1%	100.0%	17.0%	39.3%	21.3%	100.0%
Tanatriil	0.5	0.6	0.4	0.4	1.8	0.5	0.4	0.4	1.7
	24.7%	31.4%	21.8%	22.1%	100.0%	26.6%	22.4%	23.7%	100.0%
Contracted manufacturing products ^{*4}	0.9	1.2	0.5	0.8	3.4	0.6	0.5	0.4	2.1
	27.0%	34.6%	15.1%	23.2%	100.0%	27.6%	23.6%	21.3%	100.0%
Royalty income, etc.	9.5	18.4	17.0	15.5	60.4	16.2	20.6	38.9	89.6
	15.7%	30.4%	28.2%	25.7%	100.0%	18.1%	23.0%	43.3%	100.0%
Royalty from Gilenya	7.7	11.1	13.7	11.4	43.9	11.2	14.6	14.0	Undisclosed
	17.6%	25.3%	31.1%	26.0%	100.0%	-	-	-	-
Royalty from INVOKANA	Undisclosed	Undisclosed	Undisclosed	3.6	9.8	4.6	5.4	6.8	Undisclosed
	-	-	-	37.3%	100.0%	-	-	-	-
OTC products	1.2	1.0	1.0	0.8	4.0	1.2	0.9	1.0	4.1
	30.4%	24.2%	24.9%	20.4%	100.0%	28.4%	22.7%	23.2%	100.0%
Total sales	94.6	104.3	120.9	95.3	415.1	98.5	103.2	139.2	429.0
	22.8%	25.1%	29.1%	23.0%	100.0%	23.0%	24.1%	32.4%	100.0%

The each figure in the lower displays the progress rate.

*1: The Company revised the financial forecasts for FY2015 on February 3, 2016, however does not revised the forecasts of sales breakdown including sales of each product, which are indicated in italics. Achieved % of "total sales" is calculated using the revised forecasts and the others are calculated using the previous forecasts.

*2: The scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company discloses total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*3: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from the Company.

*4: Active pharmaceutical ingredients and others ordered by outside companies.

(2) State of New Product Development (As of February 3, 2016)

i. New Drugs

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
TA-7284 (canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Taiwan	Filed (Mar., 2015)	In-house
MP-513 (teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Indonesia	Filed (Apr., 2015)	In-house
		Europe	Phase 2	
		US	Phase 1	
MT-2412 (teneligliptin, canagliflozin)	Fixed-dose combination of DPP-4 inhibitor and SGLT2 inhibitor (Type 2 diabetes mellitus)	Japan	Phase 3	In-house
MP-214 (cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Japan,Asia	Phase 2b/3	Hungary: Gedeon Richter
MT-4666 (encenicline)	α 7nACh receptor agonist (Dementia of Alzheimer's type)	Japan	Phase 2	US: FORUM Pharmaceuticals
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 2	In-house
		Japan	Phase 2	
		US	Phase 1	
MT-1303 (amiselimod)	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 2	In-house
	(Psoriasis)	Europe	Phase 2	
	(Crohn's disease)	Japan,Europe	Phase 2	
	(Inflammatory diseases, autoimmune diseases)	Japan,Europe, US	Phase 1	
MT-2301	Haemophilus influenza type b (Hib) vaccine (Prophylaxis of pediatric Hib infection)	Japan	Phase 2	US: Nuron Biotech
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of seasonal influenza)	US, Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Canada	Phase 1	In-house
GB-1057 (recombinant human serum albumin)	Blood and blood forming organs	US	Phase 1	In-house
MP-124	Nervous system	US	Phase 1	In-house
MP-157	Cardiovascular system	Europe	Phase 1	In-house
MT-0814	Ophthalmologicals	Japan	Phase 1	In-house
MT-8554	Nervous system etc.	Europe	Phase 1	In-house

ii. Additional Indications

Product name (Generic name)	Category (Indications)	Region	Stage	Origin	Notes
Remicade (infliximab)	Anti-human TNF α monoclonal antibody (Psoriasis: increased dose)	Japan	sNDA filed (Jul., 2015)	US:Janssen Biotech	
	(Pediatric Crohn's disease)		Phase 3		
	(Pediatric ulcerative colitis)		Phase 3		
Tribik (adsorbed diphtheria-purified pertussis-tetanus combined vaccine)	Vaccine (Prophylaxis of pertussis, diphtheria, and tetanus; Stage 2 vaccination)	Japan	sNDA filed (Apr., 2015)	Japan:The Research Foundation for Microbial Diseases of Osaka University	Co-developed with The Research Foundation for Microbial Diseases of Osaka University
Telavic (telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [combination with Feron])	Japan	Phase 3	US:Vertex Pharmaceutic als	
Imusera (fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	In-house	Co-developed with Novartis Pharma in Japan, licensed to Novartis overseas
Canaglu (canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Global clinical trial	Phase 3	In-house	Sponsor: Janssen Research & Development, LLC

iii. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee (Notes)
TA-7284 (canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus / fixed dose combination with metformin, XR)	US	NDA filed (Nov., 2015)	US: Janssen Pharmaceuticals, Inc
	(Diabetic nephropathy)	Global clinical trial	Phase 3	
	(Type 1 Diabetes Mellitus)	US, Canada	Phase 2	
	(Obesity / co-administration with phentermine)	US	Phase 2	
FTY720 (fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	Switzerland: Novartis (Co-developed with Novartis Pharma in Japan)
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism in hemodialysis patients)	Japan	Phase 3	Japan: Kyowa Hakko Kirin
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	US: Minerva Neurosciences
MCC-847 (masilukast)	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
Wf-516	Multiple mechanisms on several receptors* (Depression)	Europe	Phase 2	US: Minerva Neurosciences
Y-803	Bromodomain inhibitor (Cancer)	Europe, Canada	Phase 2	US: Merck
sTU-199 (tenatoprazole)	Alimentary tract and metabolism	Europe	Phase 1	France: Negma/Sidem

*SSRI, 5-HT1A, dopamine transporter, and alpha-1A and B

iv. Changes Since Previous Announcement on October 30, 2015

(1) In-house Development

Development code/ product name (Generic name)	Category (Indications)	Region	As of October 30, 2015	As of February 3, 2016
TA-650 (infliximab)	Anti-human TNF α monoclonal antibody (Crohn's disease, ulcerative colitis, pediatric Crohn's disease, pediatric ulcerative colitis)	Taiwan	Filed (Sep., 2013)	Approved (Sep., 2015)
MCI-186 (edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Korea	Filed (Jun., 2015)	Approved (Dec., 2015)
Remicade (infliximab)	Anti-human TNF α monoclonal antibody (Refractory Kawasaki disease*)	Japan	sNDA filed (May, 2015)	Approved (Dec., 2015)

* Orphan drug designated

(2) Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of October 30, 2015	As of February 3, 2016
TA-7284 (canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus / fixed dose combination with metformin, XR)	US	Phase 3	NDA filed (Nov., 2015)
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism in hemodialysis patients)	Japan	Phase 2	Phase 3
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Termination of license agreement